Oncolytics Biotech (ONCY) Net Income (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Net Income data on file, last reported at -$10.5 million in Q3 2025.

• On a quarterly basis, Net Income fell 49.57% year-over-year to -$10.5 million in Q3 2025; TTM through Dec 2025 was -$19.6 million, a 188.0% decrease from a year earlier, with the FY2025 full-year figure at -$28.8 million, down 224.17% from the prior year.
• Net Income for Q3 2025 stood at -$10.5 million, down from -$4.4 million in the prior quarter.
• Over the last five years, Net Income for ONCY reached as high as $39.7 million in Q4 2024 and fell as low as -$10.5 million in Q3 2025.
• Historically, Net Income has averaged $3.7 million across 5 years, with a median of -$4.4 million in 2025.
• Across the five-year window, Net Income plunged 1805.46% in 2021 and jumped 1267.27% in 2024, its largest moves.
• Year by year, Net Income stood at $35.6 million in 2021, then decreased by 14.88% to $30.3 million in 2022, then tumbled by 90.42% to $2.9 million in 2023, then surged by 1267.27% to $39.7 million in 2024, then slumped by 126.38% to -$10.5 million in 2025.
• Per Business Quant data, the three most recent Net Income figures were -$10.5 million in Q3 2025, -$4.4 million in Q2 2025, and -$4.7 million in Q1 2025.